Corneal endothelial dystrophy

Summary

Corneal endothelial dystrophy (MONDO:0000766) is a disease and 7 clinical trials. Top therapeutic interventions include loteprednol etabonate, ripasudil, and vehicle. A subtype of corneal dystrophy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	corneal endothelial dystrophy
Mondo ID	MONDO:0000766
DOID	DOID:0060443
SNOMED CT	416960004
UMLS	C5441823
MedGen	1779156
GARD	0022828
Anatomy (UBERON)	UBERON:0001772
Is cancer (heuristic)	no

Also known as: corneal dystrophy (disease) of corneal epithelium

Disease family

This is a subtype of corneal dystrophy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › corneal disorder › corneal dystrophy › corneal endothelial dystrophy

Related subtypes (12): epithelial and subepithelial corneal dystrophy, epithelial-stromal TGFBI dystrophy, Finnish type amyloidosis, autosomal dominant keratitis, macular dystrophy, fenestrated sheen type, band keratopathy, superficial corneal dystrophy, stromal corneal dystrophy, posterior corneal dystrophy, Chandler syndrome, Judge Misch wright syndrome, corneal dystrophy, punctiform and polychromatic pre-descemet

Subtypes (4): Fuchs’ endothelial dystrophy, congenital hereditary endothelial dystrophy of cornea, X-linked endothelial corneal dystrophy, posterior polymorphous corneal dystrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	3
PHASE2	2
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05136443	PHASE4	COMPLETED	Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
NCT03575130	PHASE2	UNKNOWN	Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy
NCT04520321	PHASE1/PHASE2	COMPLETED	A Phase 1/ Phase 2 Study of TTHX1114(NM141)
NCT04812067	PHASE2	COMPLETED	A Safety and Efficacy Trial of TTHX1114 in People With CED
NCT05636579	PHASE1	RECRUITING	Study to Assess Safety and Tolerability of Multiple Doses of EO2002
NCT04191629	PHASE1	UNKNOWN	Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
NCT04894110	PHASE1	COMPLETED	Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LOTEPREDNOL ETABONATE	4	1
RIPASUDIL	3	2
VEHICLE	0	1